CAR-T for Glioblastoma
-
CAR-T Cell
CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a cutting-edge form of immunotherapy. It involves modifying your own T cells—a type of immune cell—to recognize and attack cancer cells that express specific markers. For glioblastoma, this therapy aims to provide a personalized treatment that could potentially extend survival and alleviate symptoms, especially when combined with other modalities.
Targets in CAR-T Therapy for Glioblastoma
In glioblastoma, certain proteins on the surface of tumor cells serve as ideal targets for CAR-T therapy due to their overexpression on cancer cells and limited presence on healthy tissues. At Bioocus, we focus on two key targets:
- GD2: This is a glycolipid antigen commonly found on glioblastoma cells, as well as other brain tumors like diffuse midline gliomas. GD2 is involved in cell signaling and is highly expressed in aggressive tumors, making it a promising marker for immune targeting.
- B7-H3: Also known as CD276, this immune checkpoint protein is overexpressed in glioblastoma and contributes to tumor evasion of the immune system. It plays a role in promoting cancer growth and suppressing immune responses, which makes it an effective target for enhancing T-cell attacks.
By engineering CAR-T cells to recognize GD2 or B7-H3, the therapy directs a focused assault on tumor cells while minimizing damage to normal brain tissue.
How CAR-T Therapy Works: The Mechanism of Action
CAR-T therapy begins with collecting a sample of your T cells through a process similar to blood donation. These cells are then genetically modified in a laboratory to express a chimeric antigen receptor (CAR)—a custom receptor that acts like a "homing device" for cancer cells.
- Recognition: The CAR on the T cells binds specifically to GD2 or B7-H3 on glioblastoma cells, much like a lock and key.
- Activation: Once bound, the CAR triggers the T cells to activate, multiply, and release signaling molecules that rally other immune cells to join the fight.
- Destruction: The activated T cells directly attack and kill the targeted cancer cells, potentially leading to tumor shrinkage and reduced disease burden.
This process typically involves infusing the modified T cells back into your body, often through intravenous or targeted delivery methods to reach the brain. The goal is to create a sustained immune response that continues to monitor and eliminate residual cancer cells over time.
Our CAR-T therapies targeting GD2 and B7-H3 for Glioblastoma demonstrate promising efficacy in clinical trials.
For GD2 CAR-T, a study of 37 patients with relapsed or refractory high-grade gliomas showed a 72% objective response rate, with 42% achieving complete remission at 6 weeks and 56% maintaining it at 1.7 years follow-up.
For B7-H3 CAR-T, a trial of 39 adults with recurrent glioblastoma reported a 30–40% response rate and 60–70% disease control rate, with median survival of 11 months (monotherapy) and 13.6 months (combination), surpassing historical data.
Both therapies are safe, with mild, manageable side effects. Bioocus is dedicated to advancing these innovative treatments to improve outcomes for glioblastoma patients.
Radiation Therapy
Stereotactic radiotherapy (SRT) or stereotactic body radiotherapy (SBRT) can be combined with CAR-T to precisely target tumor areas, reducing size and enhancing immune cell access. This high-precision method minimizes damage to healthy tissue and may improve CAR-T penetration.
Interventional Procedures
Particle implantation involve placing radioactive particles directly into the tumor for localized radiation, complementing CAR-T by weakening cancer cells beforehand. For brain access, Ommaya reservoir placement allows for direct drug delivery into the cerebrospinal fluid, potentially boosting CAR-T distribution.
Ommaya Reservoir
This specialized device, surgically placed under the scalp, allows direct delivery of drugs into the cerebrospinal fluid via a catheter to the brain ventricles. For glioblastoma patients, particularly those with leptomeningeal spread, the Ommaya reservoir enables precise administration of CAR-T cells or other therapies, ensuring higher drug concentrations in the central nervous system with minimal discomfort compared to lumbar punctures.
This multi-modal strategy aims to maximize control over the disease while supporting your recovery and well-being.
Frequently Asked Questions
- Am I eligible for CAR-T therapy?Eligibility depends on factors like tumor type, prior treatments, and overall health. A consultation with our specialists can help determine if it's suitable for you.
- What are the potential side effects?Common ones include fatigue, inflammation-related symptoms, and immune reactions, which are monitored and managed closely.
- How long does the process take?From cell collection to infusion, it typically spans several weeks, with follow-up care ongoing.
If you're considering CAR-T therapy for glioblastoma, we're here to support you with compassionate, evidence-based care. Contact our team at Bioocus to schedule a consultation and learn how this innovative approach might fit into your treatment plan. Your health and hope matter to us—let's explore options together.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.